Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen

References

• Abrey L E, Yahalom J, DeAngelis L M. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144–3150
   PubMed Web of Science ®Google Scholar
• DeAngelis L M, Yahalom J, Thaler H T, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10: 635–643
   PubMed Web of Science ®Google Scholar
• Freilich R J, Delattre J Y, Monjour A, DeAngelis L M. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46: 435–439
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber M L, Cher L, Hochberg F H. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188–195
   PubMed Web of Science ®Google Scholar
• O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519–526
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup S M, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998; 16: 3000–3006
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tanaka R. Advances for the treatment of primary central nervous system lymphoma (Review). Oncol Rep 2004; 12: 563–568
   PubMed Web of Science ®Google Scholar
• Blay J Y, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86: 2922–2929
   PubMed Web of Science ®Google Scholar
• Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998; 40: 1157–1162
   PubMed Web of Science ®Google Scholar
• Poortmans P, Kluin-Nelemans H C, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483–4488
   PubMed Web of Science ®Google Scholar
• Abrey L E, DeAngelis L M, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–863
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri A J, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 1999; 79: 530–534
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh G R, Hochberg F H. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996; 46: 1757–1759
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, et al. Modified ProMACE-MOPP Hybrid Regimen with moderate dose methotrexate for Patients with Primary CNS Lymphoma. Ann Hematol 2005; 84: 447–455
   PubMed Web of Science ®Google Scholar
• Endo S, Zhang S J, Saito T, Kouno M, Kuroiwa T, Washiyama K, et al. Primary malignant lymphoma of the brain: mutation pattern of rearranged immunoglobulin heavy chain gene. Jpn J Cancer Res 2002; 93: 1308–1316
   PubMedGoogle Scholar
• Bessell E M, Graus F, Lopez-Guillermo A, Villa S, Verger E, Petit J, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2001; 50: 457–464
   PubMed Web of Science ®Google Scholar
• Omuro A M, Ben-Porat L S, Panageas K S, Kim A K, Correa D D, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005; 62: 1595–1600
   PubMed Web of Science ®Google Scholar
• Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001; 71: 118–122
   PubMed Web of Science ®Google Scholar
• O'Brien P C, Roos D E, Pratt G, Liew K H, Barton M B, Poulsen M G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006; 64: 408–413
   PubMed Web of Science ®Google Scholar
• Neuwelt E A, Goldman D L, Dahlborg S A, Crossen J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9: 1580–1590
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf I G, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy. J Clin Oncol 2003; 21: 4489–4495
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schabet M, Brugger W, Kortmann R D, Kuker W, Deckert M, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51: 247–252
   PubMed Web of Science ®Google Scholar
• Plotkin S R, Betensky R A, Hochberg F H, Grossman S A, Lesser G J, Nabors L B, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643–5646
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen H A, Birkmann J, Jahnke K, Martus P, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141–1145
   PubMed Web of Science ®Google Scholar
• Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40: 1682–1688
   PubMed Web of Science ®Google Scholar
• Enting R H, Demopoulos A, DeAngelis L M, Abrey L E. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63: 901–903
   PubMed Web of Science ®Google Scholar